Abstract GS02-08: Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
Reshma Jagsi(Emory University), Mahmoud El‐Tamer(Memorial Sloan Kettering Cancer Center), Gary M. Freedman(Fox Chase Cancer Center), Jean L. Wright(University of North Carolina at Chapel Hill), Abram Recht(Beth Israel Deaconess Medical Center), William Small(Northwestern University), Kent A. Griffith(University of Michigan), Mahvish Muzaffar(East Carolina University), Meena S. Moran(Cleveland Clinic), Anne F. Schott(University of Michigan), Simon N. Powell(Memorial Sloan Kettering Cancer Center), Kathleen C. Horst(Stanford University), Bruce G. Haffty(Rutgers, The State University of New Jersey), Alphonse G. Taghian(Massachusetts General Hospital), Eleanor Harris(St. Luke's University Health Network), Jody Sharp(University of Michigan), Michael S. Sabel(Michigan Cancer Research Consortium), Asal Rahimi(Jackson Memorial Hospital), Candice Johnstone(Medical College of Wisconsin), Lucille Lee(Northwell Health)
Cited by 1
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k